Aruna Rajan, S Ramakrishnan, Madhumitha, Mohini Sethi Kara, Jabacsmick Sharmila, Priyanka Raghunathan, Mangayarkarasi, Sofia Mercy
{"title":"阿达木单抗在免疫失调引起的复发性妊娠丢失中的作用:一个病例系列报告。","authors":"Aruna Rajan, S Ramakrishnan, Madhumitha, Mohini Sethi Kara, Jabacsmick Sharmila, Priyanka Raghunathan, Mangayarkarasi, Sofia Mercy","doi":"10.1007/s13224-024-02083-4","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor necrosis factor-alpha, a multifunctional T-helper 1 (Th1) cytokine, plays a significant role in placentation and embryonic development. Altered expression of TNF-α has been implicated in adverse pregnancy outcomes such as recurrent pregnancy loss (RPL) and pre-eclampsia (PE). The use of TNF-α inhibitors (TNFi) like Adalimumab (AD) has garnered attention for its ability to traverse the placental barrier, and modulating maternal immune responses during pregnancy. In this article, we have discussed two patients in whom the immunological factors have been identified in otherwise unexplained RPL and how the use of TNFi could be of help to achieve a viable pregnancy.</p>","PeriodicalId":51563,"journal":{"name":"Journal of Obstetrics and Gynecology of India","volume":"75 Suppl 1","pages":"644-646"},"PeriodicalIF":0.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085429/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Role of Adalimumab in Recurrent Pregnancy Loss Due Immune Dysregulation: A Case Series Report.\",\"authors\":\"Aruna Rajan, S Ramakrishnan, Madhumitha, Mohini Sethi Kara, Jabacsmick Sharmila, Priyanka Raghunathan, Mangayarkarasi, Sofia Mercy\",\"doi\":\"10.1007/s13224-024-02083-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tumor necrosis factor-alpha, a multifunctional T-helper 1 (Th1) cytokine, plays a significant role in placentation and embryonic development. Altered expression of TNF-α has been implicated in adverse pregnancy outcomes such as recurrent pregnancy loss (RPL) and pre-eclampsia (PE). The use of TNF-α inhibitors (TNFi) like Adalimumab (AD) has garnered attention for its ability to traverse the placental barrier, and modulating maternal immune responses during pregnancy. In this article, we have discussed two patients in whom the immunological factors have been identified in otherwise unexplained RPL and how the use of TNFi could be of help to achieve a viable pregnancy.</p>\",\"PeriodicalId\":51563,\"journal\":{\"name\":\"Journal of Obstetrics and Gynecology of India\",\"volume\":\"75 Suppl 1\",\"pages\":\"644-646\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085429/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Obstetrics and Gynecology of India\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13224-024-02083-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obstetrics and Gynecology of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13224-024-02083-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
The Role of Adalimumab in Recurrent Pregnancy Loss Due Immune Dysregulation: A Case Series Report.
Tumor necrosis factor-alpha, a multifunctional T-helper 1 (Th1) cytokine, plays a significant role in placentation and embryonic development. Altered expression of TNF-α has been implicated in adverse pregnancy outcomes such as recurrent pregnancy loss (RPL) and pre-eclampsia (PE). The use of TNF-α inhibitors (TNFi) like Adalimumab (AD) has garnered attention for its ability to traverse the placental barrier, and modulating maternal immune responses during pregnancy. In this article, we have discussed two patients in whom the immunological factors have been identified in otherwise unexplained RPL and how the use of TNFi could be of help to achieve a viable pregnancy.
期刊介绍:
Journal of Obstetrics and Gynecology of India (JOGI) is the official journal of the Federation of Obstetrics and Gynecology Societies of India (FOGSI). This is a peer- reviewed journal and features articles pertaining to the field of obstetrics and gynecology. The Journal is published six times a year on a bimonthly basis. Articles contributed by clinicians involved in patient care and research, and basic science researchers are considered. It publishes clinical and basic research of all aspects of obstetrics and gynecology, community obstetrics and family welfare and subspecialty subjects including gynecological endoscopy, infertility, oncology and ultrasonography, provided they have scientific merit and represent an important advance in knowledge. The journal believes in diversity and welcomes and encourages relevant contributions from world over. The types of articles published are: · Original Article· Case Report · Instrumentation and Techniques · Short Commentary · Correspondence (Letter to the Editor) · Pictorial Essay